Mymetics

Mymetics ROE

The Return on Equity (ROE) of Mymetics (MYMX) as of Oct 18, 2026 is 7.40 %. In the previous year, Return on Equity (ROE) was 7.87 % — a change of -5.94% (lower).

ROE

7.40 %

YoY

-5.94%

Last updated:

In 2022, Mymetics's return on equity (ROE) was 7.40 %, a -5.94% increase from the 7.87 % ROE in the previous year.

The Mymetics ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2015
9.14 EUR
Jan 1, 2016
15.38 EUR
Jan 1, 2017
9.59 EUR
Jan 1, 2018
8.87 EUR
Jan 1, 2019
8.18 EUR
Jan 1, 2020
7.51 EUR
Jan 1, 2021
7.87 EUR
Jan 1, 2022
7.40 EUR
The Mymetics ROE history
YEARROEYoY
7.40 %-5.94%
7.87 %+4.79%
7.51 %-8.15%
8.18 %-7.82%
8.87 %-7.49%
9.59 %-37.64%
15.38 %+68.28%
9.14 %-15.55%
10.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mymetics Stock analysis

What does Mymetics do? Mymetics Corp, listed under the ticker MYMX with ISIN US62856A3005, is a biotechnology company based in Epalinges, Switzerland. The company operates within the Health Care sector, specifically in the Biotechnology industry. Mymetics Corp has an employee count of 8 and went public on February 10, 1995. The company's website is https://www.mymetics.com/. Mymetics Corp focuses on the research and development of virosome-based vaccines for infectious diseases. Virosomes are lipid-based carriers that incorporate functional fusion viral proteins and natural membrane proteins, combined with rationally designed antigens. The company has multiple vaccine candidates in its pipeline, including those targeting HIV-1/AIDS, influenza, malaria, herpes simplex virus (HSV), and respiratory syncytial virus (RSV). The HIV-1 vaccine candidate utilizes virosomes linked to conserved antigens derived from HIV-1 glycoprotein 41 (gp41) proteins of clade B. The RSV vaccine candidate is composed of reconstituted RSV membrane containing native viral proteins. Similarly, the HSV vaccine candidate consists of reconstituted membranes from HSV-1 or HSV-2, while the intranasal influenza vaccine includes reconstituted influenza virus membranes. Mymetics Corp's technology aims to develop prophylactic vaccines through these virosome-based approaches. The company's headquarters are located in Epalinges, Vaud, Switzerland. The firm's current focus is on advancing its pipeline of vaccine candidates for various infectious diseases through innovative virosome technology. Mymetics is one of the most popular companies on Eulerpool.

ROE Details

Decoding Mymetics's Return on Equity (ROE)

Mymetics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Mymetics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Mymetics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Mymetics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Mymetics stock

Return on Equity (ROE) of Mymetics is 7.40 % in 2022.

Return on Equity (ROE) of Mymetics changed from 7.87 % to 7.40 %, representing a -5.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Mymetics since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Mymetics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Mymetics

All Key Metrics — Mymetics